Table 3.
Top 10 funders of patient organisations (2012-16)
| Company | Value of payments (£) | No of payments | Median (interquartile range) payment (£) | Largest single payment (£) |
|---|---|---|---|---|
| Pfizer | 9 580 192 | 909 | 1029 (263 to 6072) | 3 505 563 |
| Takeda | 6 614 468 | 55 | 3000 (1014 to 14 200) | 5 924 160 |
| Novartis | 5 409 1990 | 447 | 7605 (758 to 15 255) | 157 350 |
| AbbVie | 3 619 5350 | 289 | 4040 (655 to 13 466) | 244 907 |
| Lilly | 3 284 206 | 258 | 2749 (447 to 16 178) | 269 819 |
| Astellas | 2 928 978 | 88 | 12 741 (2035 to 30 225) | 1 025 150 |
| Sanofi | 2 593 214 | 232 | 5025 (1034 to 14 324) | 136 080 |
| Bristol-Myers Squibb | 1 929 615 | 248 | 4943 (849 to 10 521) | 82 078 |
| Celgene | 1 867 877 | 133 | 5260 (1250 to 15 211 | 111 546 |
| MSD | 1 813 144 | 253 | 3857 (514 to 9311) | 95 100 |